newsfilter
← Latest News
GlobeNewswire·

Immunocore to present at upcoming investor conferences

  • Immunocore Holdings plc announced management participation in the UBS Global Biopharma Conference 2026 fireside chat on Tuesday, November 17, 2026, at 3:20 p.m. GMT.
  • The company will host 1x1 & small group meetings at the Jefferies London Global Healthcare Conference on Wednesday, November 18, 2026.
  • Conference presentations will be webcast live via the Investors section of Immunocore's website, with a replay available for a limited time post-event.
  • Immunocore is a commercial-stage biotechnology firm developing the ImmTAX platform, a novel class of TCR bispecific immunotherapies for cancer, autoimmune diseases, & infectious diseases.
  • The company's most advanced oncology therapeutic, KIMMTRAK, is approved for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in 39 countries.
  • KIMMTRAK approvals include the United States, European Union, Canada, Australia, & the United Kingdom.
Company
Immunocore Holdings plc
Keywords
Nasdaq:IMCR, Immunocore Holdings plc, Immunocore, Investor conferences